Published in Mucosal Immunol on October 02, 2013
Ultrasound-mediated gastrointestinal drug delivery. Sci Transl Med (2015) 1.57
A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature (2015) 1.56
Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease. PLoS One (2015) 1.47
Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34
Reparative inflammation takes charge of tissue regeneration. Nature (2016) 1.21
Wound repair: role of immune-epithelial interactions. Mucosal Immunol (2015) 1.00
Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther (2013) 0.99
Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2015) 0.94
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol (2015) 0.93
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol (2016) 0.93
Neutrophil-Epithelial Interactions: A Double-Edged Sword. Am J Pathol (2016) 0.82
Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS One (2015) 0.82
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut (2015) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. Biomed Res Int (2014) 0.81
Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. Am J Pathol (2015) 0.80
The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol (2015) 0.80
Genetic deletion of IL-25 (IL-17E) confers resistance to dextran sulfate sodium-induced colitis in mice. Cell Biosci (2014) 0.80
Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J (2016) 0.79
A Microbial Feed Additive Abates Intestinal Inflammation in Atlantic Salmon. Front Immunol (2015) 0.78
Human norovirus infection and the acute serum cytokine response. Clin Exp Immunol (2015) 0.78
Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2016) 0.78
The integrin αv-TGFβ signaling axis is necessary for epidermal proliferation during cutaneous wound healing. Cell Cycle (2016) 0.78
Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Microb Cell Fact (2015) 0.76
Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol (2016) 0.76
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver (2017) 0.75
Making sense of the cause of Crohn's - a new look at an old disease. F1000Res (2016) 0.75
Structural and immunomodulatory differences among lactobacilli exopolysaccharides isolated from intestines of mice with experimentally induced inflammatory bowel disease. Sci Rep (2016) 0.75
Interleukin-17 and type 17 helper T cells in cancer management and research. Immunotargets Ther (2014) 0.75
Soluble bioactive microbial mediators regulate proteasomal degradation and autophagy to protect against inflammation-induced stress. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw (2017) 0.75
Structural and molecular features of intestinal strictures in rats with Crohn's-like disease. World J Gastroenterol (2016) 0.75
Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats. Int J Nanomedicine (2016) 0.75
Inflammatory bowel disease-related arthritis - clinical evaluation and possible role of cytokines. Reumatologia (2015) 0.75
Sizing nanomaterials in bio-fluids by cFRAP enables protein aggregation measurements and diagnosis of bio-barrier permeability. Nat Commun (2016) 0.75
Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. World J Gastroenterol (2017) 0.75
Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects. PLoS One (2016) 0.75
Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep (2017) 0.75
Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Sci Rep (2017) 0.75
Advancing Intestinal Organoid Technology Toward Regenerative Medicine. Cell Mol Gastroenterol Hepatol (2017) 0.75
G-protein coupled receptor kinase-2 is a critical regulator of TNFα signaling in colon epithelial cells. Biochem J (2017) 0.75
Analysis of endogenous lipids during intestinal wound healing. PLoS One (2017) 0.75
Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med (2017) 0.75
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Tumor necrosis factor signaling. Cell Death Differ (2003) 8.48
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature (2007) 7.17
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
Ulcerative colitis. N Engl J Med (2011) 6.14
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Rho GTPases and the control of cell behaviour. Biochem Soc Trans (2005) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology (2005) 5.26
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 5.14
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 4.94
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology (2005) 4.68
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
Crohn's disease. Lancet (2012) 4.42
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev (2006) 4.40
The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A (2010) 4.35
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med (2005) 4.28
Trichuris suis therapy in Crohn's disease. Gut (2005) 4.05
Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 4.04
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature (2011) 3.61
Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity (2002) 3.46
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 3.41
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest (2005) 3.36
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.35
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis (2006) 3.29
The role of Th1/Th2 polarization in mucosal immunity. Nat Med (2002) 3.19
Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol (2006) 3.16
RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology (2008) 3.13
Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med (2009) 2.82
T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med (1996) 2.79
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest (1994) 2.51
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut (2008) 2.50
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.45
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol (2011) 2.44
Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41
IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol (1998) 2.40
Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut (2005) 2.37
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis (2009) 2.26
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol (2011) 2.19
Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology (2002) 2.19
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology (1993) 2.13
Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet (1990) 2.13
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest (2011) 2.10
CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res (2003) 2.00
Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol (2008) 1.95
Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A (2008) 1.93
Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology (2010) 1.92
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis (2011) 1.91
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut (2004) 1.82
Autophagy and the immune system. Annu Rev Immunol (2012) 1.80
Autoimmunity: The worm returns. Nature (2012) 1.77
Predicting the response to infliximab from trough serum levels. Gut (2010) 1.76
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut (2012) 1.73
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology (2005) 1.66
Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol (2012) 1.56
Mucin function in inflammatory bowel disease: an update. J Clin Gastroenterol (2013) 1.55
IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med (2010) 1.54
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut (2010) 1.53
Selective adhesion-molecule therapy and inflammatory bowel disease--a tale of Janus? N Engl J Med (2005) 1.50
Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest (1993) 1.48